Alvotech Teams Up with Advanz Pharma To Launch Eylea Biosimilar

Alvotech and Advanz Pharma have entered into an exclusive partnership deal concerning the distribution and marketing of AVT06, Alvotech's proposed biosimilar to Eylea in its low dose form (2mg), along with AVT29, a biosimilar candidate for Eylea in its high dose form (8mg). According to the press release, Eylea is a commonly employed biological treatment for eye conditions that may result in vision loss or blindness, such as wet AMD, macular edema, and diabetic retinopathy.

Under this agreement, Alvotech will handle the development and supply of AVT06 and AVT29, while Advanz Pharma will manage their registration and commercialization. Advanz Pharma holds exclusive commercialization rights across Europe, except in Germany and France where the rights are partially exclusive. The agreement involves an initial payment to Alvotech, along with additional payments upon achieving specific development and commercialization milestones.

Anil Okay, Chief Commercial Officer (CCO) of Alvotech, said that “We value our growing partnership with Advanz Pharma which started early last year and has now been expanded to a total of seven biosimilar candidates. We share a common vision for the growth of the biosimilars market and a strong commitment to providing broader patient access to more affordable biologics.”